RepligenRGEN +4.94%84 10-Year RORE % is 5.53 as of Mar. 2026. GuruFocus rates RGEN with a GF Score™ of 84/100 and a GF Value™ of $176.53 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 428 Medical Devices & Instruments companies, Repligen ranks better than 59.35% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Repligen's 10-Year RORE % for the quarter that ended in Mar. 2026 was 5.53%.
The industry rank for Repligen's 10-Year RORE % or its related term are showing as below:
RGEN's 10-Year RORE % is ranked better than 59.35% of 428
companies
in the Medical Devices & Instruments industry
Industry Median: 0.735
vs RGEN: 5.53
Repligen (NAS:RGEN) 10-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Repligen 10-Year RORE % Related Terms
Repligen 10-Year RORE % Historical Data
* Premium members only.
The historical data trend for Repligen's 10-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Repligen's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repligen 10-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Repligen's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
Repligen (RGEN) has a 10-Year RORE % of 5.53 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Repligen and its competitors. According to the industry distribution chart, Repligen ranks #174 out of 428 companies in the Medical Devices & Instruments industry, placing it in the top 40.7%.
Is Repligen's 10-Year RORE % too high?
Repligen's current 10-Year RORE % is 5.53. The Medical Devices & Instruments industry median 10-Year RORE % is 0.74. Repligen's value of 5.53 is 652.4% above this industry median. Based on the distribution chart, Repligen ranks #174 out of 428 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Repligen has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Repligen's 10-Year RORE % compare to ATR and AVTR?
According to the Medical Devices & Instruments industry distribution chart, Repligen ranks #174 out of 428 companies for 10-Year RORE %. This puts Repligen in the upper half of its industry. The industry median 10-Year RORE % is 0.74. Repligen's value of 5.53 is 652.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Devices & Instruments company?
The median 10-Year RORE % among Medical Devices & Instruments companies is 0.74, based on 428 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Repligen's current 10-Year RORE % of 5.53 is 652.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Repligen and its competitors. For the Medical Devices & Instruments industry, the median 10-Year RORE % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Repligen's current 10-Year RORE % is 5.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (RGEN) is currently considered Modestly Undervalued. The stock's GF Value™ is $176.53, compared to a current price of $144.29 — trading 18.3% below its estimated fair value. The current 10-Year RORE % is 5.53 and 652.4% above the Medical Devices & Instruments industry median of 0.74. Repligen's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Repligen (RGEN), the current 10-Year RORE % is 5.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Repligen (RGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Repligen stock appears to be undervalued.
The current stock price of $144.29 is trading 18.3% below its estimated GF Value™ of $176.53.
GuruFocus considers Repligen to be Modestly Undervalued.
Key valuation signals for RGEN:
10-Year RORE %: 5.53
GF Value™: $176.53 vs. price of $144.29 (18.3% below fair value)
Industry Position: 652.4% above the Medical Devices & Instruments median (#174 of 428)
No single metric tells the full story. See the RGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
84GF Score
Get the complete analysis for RGEN
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGEN has been successfully added to your 
